文献速递脑血管病

房颤患者近期脑缺血后直接口服抗凝药与维生素K拮抗剂的比较

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
PubMed 文献 · Ann Neurol · 2019-04-30

该研究基于七项前瞻性队列研究的个体患者数据,比较房颤合并近期脑缺血患者使用DOAC与VKA的结局。共纳入4912例患者,DOAC组复合终点(复发性缺血性卒中、脑出血或死亡)风险低于VKA组(HR 0.82, 95%CI 0.67-1.00, p=0.05),主要归因于脑出血风险降低(HR 0.42, 95%CI 0.24-0.71, p<0.01)。

要点

  • 房颤近期脑缺血后早期启用DOAC与VKA相比,复合终点风险有降低趋势。
  • DOAC显著降低脑出血风险,复发性缺血性卒中和死亡风险无差异。

核心结论

  • 房颤相关近期脑缺血后早期启用DOAC与VKA相比,与不良临床结局风险降低相关,主要归因于脑出血风险降低。

研究设计与样本

  • 研究为七项前瞻性队列研究的个体患者数据分析,纳入房颤合并近期脑缺血(开始口服抗凝前<3个月)且随访至少3个月的患者,共4912例。

主要发现

  • 中位年龄78岁(IQR 71-84),女性2331例(47.5%),起病时NIHSS中位评分5分(IQR 2-12)。
  • VKA组2256例(45.9%),DOAC组2656例(54.1%);从索引事件到开始口服抗凝的中位时间VKA组5天(IQR 2-14),DOAC组5天(IQR 2-11),p=0.53。
  • 总随访5970患者年期间,发生262例急性缺血性卒中(4.4%/年)、71例脑出血(1.2%/年)、439例死亡(7.4%/年)。
  • 与VKA相比,DOAC治疗与复合终点风险降低相关(HR 0.82; 95%CI 0.67-1.00; p=0.05),与脑出血风险降低相关(HR 0.42; 95%CI 0.24-0.71; p<0.01)。
  • 复发性急性缺血性卒中风险(HR 0.91; 95%CI 0.70-1.19; p=0.5)和死亡风险(HR 0.83; 95%CI 0.68-1.03; p=0.09)两组无差异。

临床怎么用

  • 对于房颤合并近期脑缺血的患者,早期启用DOAC可能较VKA降低复合不良结局风险,尤其减少脑出血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We compared outcomes after treatment with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and a recent cerebral ischemia. METHODS: We conducted an individual patient data analysis of seven prospective cohort studies. We included patients with AF and a recent cerebral ischemia (<3 months before starting oral anticoagulation) and a minimum follow-up of 3 months. We analyzed the association between type of anticoagulation (DOAC versus VKA) with the composite primary endpoint (recurrent ischemic stroke [AIS], intracerebral hemorrhage [ICH], or mortality) using mixed-effects Cox proportional hazards regression models; we calculated adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs). RESULTS: We included 4,912 patients (median age, 78 years [interquartile range {IQR}, 71-84]; 2,331 [47.5%] women; median National Institute of Health Stroke Severity Scale at onset, 5 [IQR, 2-12]); 2,256 (45.9%) patients received VKAs and 2,656 (54.1%) DOACs. Median time from index event to starting oral anticoagulation was 5 days (IQR, 2-14) for VKAs and 5 days (IQR, 2-11) for DOACs (p = 0.53). There were 262 acute ischemic strokes (AISs; 4.4%/year), 71 intracranial hemorrrhages (ICHs; 1.2%/year), and 439 deaths (7.4%/year) during the total follow-up of 5,970 patient-years. Compared to VKAs, DOAC treatment was associated with reduced risks of the composite endpoint (HR, 0.82; 95% CI, 0.67-1.00; p = 0.05) and ICH (HR, 0.42; 95% CI, 0.24-0.71; p < 0.01); we found no differences for the risk of recurrent AIS (HR, 0.91; 95% CI, 0.70-1.19; p = 0.5) and mortality (HR, 0.83; 95% CI, 0.68-1.03; p = 0.09). INTERPRETATION: DOAC treatment commenced early after recent cerebral ischemia related to AF was associated with reduced risk of poor clinical outcomes compared to VKA, mainly attributed to lower risks of ICH. ANN NEUROL 2019;85:823-834.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Seiffge DJ, Paciaroni M, Wilson D, et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol. 2019. PMID: 30980560. doi:10.1002/ana.25489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。